DUAL AGENT NANOPARTICLE COMPOSITION FOR COATING MEDICAL DEVICES
A pharmaceutical composition is described. The pharmaceutical composition includes a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent. Implantable medical devices coated with the pharmaceutical composition, methods of coating an implantable medical device with the pharmaceutical composition, and methods of treating vascular disease using the pharmaceutical composition are also described.
1 . A pharmaceutical composition, comprising a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent.
2 . The pharmaceutical composition of claim 1 , wherein the polymeric nanoparticles comprise poly(lactic-co-glycolic acid) (PLGA).
3 . The pharmaceutical composition of claim 1 , wherein the polymeric matrix comprises polyvinyl alcohol (PVA).
4 . The pharmaceutical composition of claim 1 , wherein the polymeric nanoparticles are surface-functionalized.
5 . The pharmaceutical composition of claim 4 , wherein the polymeric nanoparticles are surface-functionalized with PVA and poly-1-lysine (PLL).
6 . The pharmaceutical composition of claim 5 , wherein the polymeric nanoparticles are further surface functionalized with a cationic surfactant.
7 . The pharmaceutical composition of claim 5 , wherein the polymeric nanoparticle has a cationic zeta potential.
8 . The pharmaceutical composition of claim 1 , wherein the polymeric nanoparticles have a hydrodynamic diameter from 50 to 1000 nanometers.
9 . The pharmaceutical composition of claim 1 , wherein the first and second therapeutic agents are both antiproliferative agents.
10 . The pharmaceutical composition of claim 9 , wherein the first therapeutic agent is a limus compound, and the second therapeutic agent is a taxane compound.
11 . The pharmaceutical composition of claim 10 , wherein the first therapeutic agent is sirolimus, and the second therapeutic agent is paclitaxel.
12 . The pharmaceutical composition of claim 11 , wherein the weight ratio of paclitaxel to sirolimus ranges from about 8:1 w/w to about 10:1 w/w.
13 . The pharmaceutical composition of claim 11 , wherein the weight ratio of sirolimus to paclitaxel ranges from about 8:1 w/w to about 10:1 w/w.
14 . The pharmaceutical composition of claim 11 , wherein the weight ratio of sirolimus to paclitaxel ranges from about 1:2 w/w to about 2:1 w/w.
15 . The pharmaceutical composition of claim 11 , wherein the sirolimus and/or the paclitaxel is amorphous.
16 . The pharmaceutical composition of claim 1 , wherein the polymeric nanoparticles further comprise L-(+)-tartaric acid dimethyl ester or a fatty acid.
17 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an imaging agent.
18 . The pharmaceutical composition of claim 1 , wherein the first and second therapeutic agents are present in different polymeric nanoparticles.
19 . The pharmaceutical composition of claim 1 , wherein the first and second therapeutic agents are present within the same polymeric nanoparticles.
20 . The pharmaceutical composition of claim 1 , wherein the first therapeutic agent and/or the second therapeutic agent is solubilized.
21 . A coated implantable medical device, wherein at least a portion of the implantable medical device is coated with pharmaceutical composition, comprising a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent.
22 . The coated implantable medical device of claim 21 , wherein the implantable medical device is a stent or a balloon catheter.
23 . The coated implantable medical device of claim 21 , wherein the polymeric nanoparticles comprise poly(lactic-co-glycolic acid) (PLGA).
24 . The coated implantable medical device of claim 21 , wherein the polymeric matrix comprises polyvinyl alcohol (PVA).
25 . The coated implantable medical device of claim 21 , wherein the polymeric nanoparticles are surface-functionalized with PVA and poly-1-lysine (PLL).
26 . The coated implantable medical device of claim 21 , wherein the polymeric nanoparticles have a hydrodynamic diameter from 50 to 1000 nanometers.
27 . The coated implantable medical device of claim 21 , wherein the pharmaceutical composition is coated with an outer layer of polyvinyl alcohol.
28 . The coated implantable medical device of claim 27 , wherein the outer layer further comprises a sugar and glycerin.
29 . A method of treating vascular disease in a subject, comprising placing a coated implantable medical device into a blood vessel of a subject having vascular disease, wherein at least a portion of the implantable medical device is coated with pharmaceutical composition, comprising a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent.
30 . The method of claim 29 , wherein the vascular disease is peripheral artery disease.
31 . The method of claim 29 , wherein the vascular disease is restenosis.
32 . The method of claim 29 , wherein the vascular disease is coronary artery disease.
33 . The method of claim 29 , wherein the implantable medical device is a stent or a balloon catheter.
34 . The method of claim 29 , wherein the polymeric nanoparticle comprises poly(lactic-co-glycolic acid) (PLGA).
35 . The method of claim 29 , wherein the polymeric matrix comprises polyvinyl alcohol (PVA).
36 . The method of claim 29 , wherein the polymeric nanoparticles are surface-functionalized with PVA and poly-1-lysine (PLL).
37 . The method of claim 36 , wherein the outer layer further comprises a sugar and glycerin.
38 . The method of claim 29 , wherein the first therapeutic agent is sirolimus and the second therapeutic agent is paclitaxel.
39 . The method of claim 29 , wherein the pharmaceutical composition is coated with an outer layer of polyvinyl alcohol.
40 . The method of claim 29 , wherein the subject is human.
41 . A method of coating an implantable medical device, comprising
a) applying a pharmaceutical composition dispersed in an aqueous solution to the surface of an implantable medical device, wherein the pharmaceutical composition comprises a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent,
b) removing the aqueous solution by drying to form a layer of the pharmaceutical composition on the surface of the implantable medical device,
repeating steps a) and b) to form a coating comprising a plurality of layers on the surface of the implantable medical device.
42 . The method of claim 41 , further comprising the step of applying a base coat of polymer matrix without polymeric nanoparticles to the surface of the implantable medical device before conducting step a).
43 . The method of claim 41 , wherein the polymeric matrix comprises polyvinyl alcohol (PVA).
44 . The method of claim 41 , further comprising applying an outer coat of polymer matrix without polymeric nanoparticles to the surface of the implantable medical device after forming a coating comprising a plurality of layers on the implantable medical device.
45 . The method of claim 44 , wherein the outer layer further comprises a sugar and glycerin.
46 . The method of claim 41 , wherein the implantable medical device is a stent or a balloon catheter.